Sam Libby Joins EDP Biotech to Fuel Rapid Expansion Plans

EDP Biotech Corporation is thrilled to welcome Sam Libby as their new Head of Mergers & Acquisitions and Corporate Development. With Libby’s expertise on board, the company is looking to expand their investments and create valuable corporate relationships as they continue to grow. Libby’s knowledge and experience will prove to be invaluable in helping the company reach their ambitious goals.

EDP Biotech is proud to announce the appointment of Sam Libby as the Company’s Head of Mergers & Acquisitions and Corporate Development. Libby will be an integral part of the team, driving strategic investments, leading merger and acquisition efforts, and building strong corporate relationships. With the Company’s impressive growth and achievement of milestones far exceeding expectations, Libby’s expertise and knowledge will be invaluable in helping to realize our ambitious goals.

Libby is thrilled to join the EDP Biotech team, bringing with him almost a decade of experience in healthcare investment banking. Libby has advised clients on a diverse range of transactions, including mergers and acquisitions, public and private equity financings, and other strategic alternatives. To date, Libby has successfully completed over 30 transactions, with a combined valuation of more than $20 billion, across various healthcare verticals.

I am delighted to be joining the EDP Biotech team. I have had the pleasure of working with Eric Mayer and the EDP management team in a banking capacity, and I am a staunch believer in their patient-focused approach and goal to make early-stage cancer detection more accessible. I am very excited to be part of such a dynamic and forward-thinking organization.

Eric Mayer, CEO of EDP Biotech, believes that Libby’s experience and knowledge, which is centered around getting ahead of diseases to improve patient lives, are values that are deeply shared by the company. His philosophy of making a difference in the lives of those affected by illness is something that resonates within the organization.

The Company is thrilled to welcome Libby to our team – her addition will be instrumental in helping to achieve our growth goals, while also allowing us to remain focused on our mission of improving patient lives. We look forward to the value and impact she will bring to the team!

About EDP Biotech Corporation

At EDP Biotech, we are passionate about early-detection of diseases and helping people live healthier lives. Founded in 2005, we are a privately held ISO 13485:2016 and CLIA certified laboratory specializing in the development, commercialization, and diagnostic and companion CRO services of in vitro biomarker assays, and clinical patient and community testing in oncology, infectious disease and women’s health. Our first commercial product, ColoPlex™, is a groundbreaking multimarker in vitro diagnostic assay for the detection of colorectal cancer and pre-cancerous cancer polyps.

Leave a Comment